ClinicalTrials.gg
Active, not recruitingNCT06712407NefXtendUpdated Sep 24, 2026

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

A Phase 4 interventional study of TARPEYO® in IgA Nephropathy, sponsored by Calliditas Therapeutics AB. Active, not recruiting at 38 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Calliditas Therapeutics AB · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 74 studies in Glomerulonephritis, IGA with a site in United States — 26 open to participants now, 38 under way, 17 of them phase 3. Glomerulonephritis, IGA · United States.

Planned enrollment
35th of 68
60 · median 64
Started
2024
with 5 others
Phase 4
7 of 74
1 open now
Primary completion
2027-03
later than 6 of 37 live
Registered
52nd of 74
by date
Lead sponsor
3 of 74
Calliditas Therapeutics AB

Among the 74 studies in Glomerulonephritis, IGA with a site in United States, this one is the 35th largest by planned enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2024, is one of 7 in phase 4, reaches primary completion later than 6 of the 37 other live ones, and was the 52nd registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

26 of the 74 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is:

Is there a treatment benefit of TARPEYO® 16 mg QD extended use?

Participants will

  • take part in this study for about 19 months
  • Have urine tests done
  • Have blood samples taken
  • Have physical examinations done
Read the detailed description

This clinical trial will investigate the efficacy and safety of TARPEYO® treatment extended for an additional 15 months in adult IgAN participants who have completed their initial, single 9-month TARPEYO® 16 mg QD commercial treatment regimen. Participants with residual proteinuria will be eligible for enrollment. The Treatment Period will consist of a 6-month Treatment Period with TARPEYO® 16 mg QD, followed by a 9-month Treatment Period with TARPEYO® 8 mg QD. This will be followed by a 3-month Follow-up Period, which includes the first 2 weeks of Tapering Period with TARPEYO® 4 mg QD.

The overall aim of the extended treatment is to improve and maintain the treatment effect with reduced proteinuria and protection of kidney function over a total of 2 years of TARPEYO® treatment.

03

Conditions studied

  • IgA Nephropathy

Keywords

  • TARPEYO®
  • IgAN
  • urine protein-to-creatinine
  • ESRD
  • Nefecon
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed IgAN with verification
  2. Female or male participants ≥18 years of age
  3. Completion of a single, initial 9 months of treatment with TARPEYO® 16 mg QD at the Baseline visit
  4. Access to retrospective local laboratory assessment data on UPCR and serum creatinine. Available retrospective data should include at least 1 assessment timepoint within 3 months prior to the first dose of TARPEYO® commercial treatment.
  5. On stable treatment with renin-angiotensin system (RAS) inhibitor therapy or sparsentan for at least 8 weeks prior to the Baseline visit. A stable dose is defined as a dose within 25% of the dose at Baseline.
  6. If on current treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitor, the treatment should have been stable for at least 8 weeks prior to the Baseline visit. A stable dose is defined as a dose within 25% of the dose at Baseline.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have been treated with systemic medications including glucocorticosteroids (GCS) other than TARPEYO® during the TARPEYO® commercial treatment period. Topical or inhalation products containing GCS or immunosuppressants are allowed.
  2. Presence of other glomerulopathies (e.g., C3 glomerulopathy, diabetes nephropathy and/or hypertensive nephropathy).
  3. Presence of nephrotic syndrome (i.e., proteinuria >3.5 g per day and serum albumin \<3.0 g/dL, with or without edema).
  4. Presence of medical condition excluding continued TARPEYO® treatment, as assessed by the Investigator.
  5. On current or planned dialysis.
  6. Undergone kidney transplant.
  7. Poorly controlled diabetes mellitus or hypertension, as assessed by the Investigator.
  8. Participants with known osteoporosis in the medium- or high-risk category according to the 2010 American College of Rheumatology recommendations.
  9. Any medical or social circumstance making trial participation and/or TARPEYO® treatment unsuitable, as assessed by the Investigator.
  10. Participants with infections that put the participant at risk, at the discretion of the Investigator.
  11. Participants unwilling or unable to meet the requirements of the protocol.
  12. Intake of another drug during trial, or during the preceding 9-monthcommercial TARPEYO® treatment period.
  13. Females who are pregnant, breastfeeding, or plan to become pregnant in the trial period.
  14. Participants taking potent inhibitors of cytochrome P450 (CYP) 3A4
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    16 mg QD then 8 mg QD

    6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.

    Drug: TARPEYO®

Interventions

  • 6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.

    Also known as: delayed-release budesonide capsules

06

What researchers measure

Primary outcomes

  1. Ratio of Urine Protein to Creatine Ratio (UPCR) at 6 months compared to Baseline

    The outcome is measured as UPCR (based on 24-hour urine collection) at 6 months following the first dose of TARPEYO® trial treatment compared to study Baseline. Ratio being UPCR at 6 months in g/gram divided with UPCR at Baseline in g/gram.

    Time frame: 6 months

Secondary outcomes

  1. Ratio of Urine Protein to Creatine Ratio (UPCR) at 15 months compared to Baseline

    The outcome is measured as UPCR (based on 24-hour urine collection) at 15 months following the first dose of TARPEYO® trial treatment compared to study Baseline. Ratio being UPCR at 15 months in g/gram divided with UPCR at Baseline in g/gram.

    Time frame: 15 months

  2. Ratio of Urine Protein to Creatine Ratio (UPCR) at 6 months compared to prior to start of TARPEYO® commercial treatment (i.e., comparison with retrospective local laboratory data from medical records as available)

    Ratio of UPCR (based on 24-hour urine collection) at 6 months compared to prior to start of TARPEYO® commercial treatment (i.e., comparison with retrospective local laboratory data from medical records as available). Retrospective data will be collected up to 3 months prior to start of commercial treatment and during the duration of the commercial treatment. Ratio being UPCR at 6 months in g/gram divided with UPCR prior to commercial treatment in g/gram

    Time frame: 18 months

  3. Ratio of Urine Protein to Creatine Ratio (UPCR) at 15 months compared to prior to start of TARPEYO® commercial treatment (i.e., comparison with retrospective local laboratory data from medical records as available)

    Ratio of UPCR (based on 24-hour urine collection) at 15 months compared to prior to start of TARPEYO® commercial treatment (i.e., comparison with retrospective local laboratory data from medical records as available). Retrospective data will be collected up to 3 months prior to start of commercial treatment and during the duration of the commercial treatment. Ratio being UPCR at 6 months in g/gram divided with UPCR prior to commercial treatment in g/gram

    Time frame: 27 months

  4. Ratio of estimated glomerular filtration rate (eGFR) at 6 months compared to Baseline

    The outcome is measured as ratio of eGFR in mL/min/1.73 m2 (calculated using the CKD-EPI formula) at 6 months following the first dose of TARPEYO® trial treatment compared to study baseline.

    Time frame: 6 months

  5. Ratio of estimated glomerular filtration rate (eGFR) at 15 months compared to Baseline

    The outcome is measured as ratio of eGFR in mL/min/1.73 m2 (calculated using the CKD-EPI formula) at 15 months following the first dose of TARPEYO® trial treatment compared to study baseline.

    Time frame: 15 months

  6. Ratio of estimated glomerular filtration rate (eGFR) at 6 months compared to start of TARPEYO® commercial treatment (i.e., comparison with retrospective local laboratory data from medical records as available)

    The outcome is measured as ratio of eGFR in mL/min/1.73 m2 (calculated using the CKD-EPI formula) at 6 months following the first dose of TARPEYO® trial treatment compared to start of commercial treatment. Retrospective data will be collected up to 3 months prior to start of commercial treatment and during the duration of the commercial treatment.

    Time frame: 18 months

  7. Ratio of estimated glomerular filtration rate (eGFR) at 15 months compared to start of TARPEYO® commercial treatment (i.e., comparison with retrospective local laboratory data from medical records as available)

    The outcome is measured as ratio of eGFR in mL/min/1.73 m2 (calculated using the CKD-EPI formula) at 15 months following the first dose of TARPEYO® trial treatment compared to start of commercial treatment. Retrospective data will be collected up to 3 months prior to start of commercial treatment and during the duration of the commercial treatment.

    Time frame: 27 months

  8. Ratio of 24-hour urine proteinuria at 6 months compared to Baseline

    The outcome is measured as proteinurea (based on 24-hour urine collection) at 6 months following the first dose of TARPEYO® trial treatment compared to study Baseline. Ratio being proteinurea at 6 months in g/day divided with proteinurea at Baseline in g/day.

    Time frame: 6 months

  9. Ratio of 24-hour urine proteinuria at 15 months compared to Baseline

    The outcome is measured as proteinurea (based on 24-hour urine collection) at 6 months following the first dose of TARPEYO® trial treatment compared to study Baseline. Ratio being proteinurea at 15 months in g/day divided with proteinurea at Baseline in g/day.

    Time frame: 15 months

  10. Proportion of participants with microhematuria at 6 months

    Number of participants with microhematuria at 6 months divided by total number of participants.

    Time frame: 6 months

  11. Proportion of participants with microhematuria at 15 months

    Number of participants with microhematuria at 15 months divided by total number of participants.

    Time frame: 15 months

  12. To evaluate the safety (SAEs and AEs) of extended TARPEYO® treatment

    SAEs and AEs will be evaluated and reported.

    Time frame: 19 months

07

Study locations

38 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Mar 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Dec 2, 2024
StartActual
Dec 17, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Feb 2028
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06712407
Lead sponsor
Calliditas Therapeutics AB
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Dec 17, 2024
Primary completion
Mar 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

Krassimir Mitchev
study director · Calliditas Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion